"Cyclooxygenase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS.
| Descriptor ID |
D051546
|
| MeSH Number(s) |
D08.811.600.720.750
|
| Concept/Terms |
Cyclooxygenase 2- Cyclooxygenase 2
- Cyclo-Oxygenase II
- Cyclo Oxygenase II
- PTGS2
- PGHS-2
- Prostaglandin H Synthase-2
- Prostaglandin H Synthase 2
- COX-2 Prostaglandin Synthase
- COX 2 Prostaglandin Synthase
- Prostaglandin Synthase, COX-2
- Synthase, COX-2 Prostaglandin
- Cyclooxygenase-2
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2".
This graph shows the total number of publications written about "Cyclooxygenase 2" by people in this website by year, and whether "Cyclooxygenase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 12 | 9 | 21 |
| 2018 | 8 | 8 | 16 |
| 2019 | 2 | 3 | 5 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclooxygenase 2" by people in Profiles.
-
Comparative Anti-Inflammatory Effects of Salix Cortex Extracts and Acetylsalicylic Acid in SARS-CoV-2 Peptide and LPS-Activated Human In Vitro Systems. Int J Mol Sci. 2021 Jun 23; 22(13).
-
A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19). Curr Med Sci. 2021 Apr; 41(2):297-305.
-
Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. J Immunol. 2021 01 15; 206(2):329-334.
-
Effect of Ergothioneine on 7-Ketocholesterol-Induced Endothelial Injury. Neuromolecular Med. 2021 03; 23(1):184-198.
-
Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci Immunol. 2020 09 17; 5(51).
-
What about COVID-19 and arachidonic acid pathway? Eur J Clin Pharmacol. 2020 Nov; 76(11):1501-1504.
-
DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1. Sci Rep. 2020 06 23; 10(1):10187.
-
Which type of cancer patients are more susceptible to the SARS-COX-2: Evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol. 2020 Sep; 153:103032.
-
Regulation of YAP by Mammalian Target of Rapamycin Complex 1 in Endothelial Cells Controls Blood Pressure Through COX-2/mPGES-1/PGE2 Cascade. Hypertension. 2019 10; 74(4):936-946.
-
Cyclooxygenase-2 Gene Polymorphisms and Risk of Alzheimer's Disease: A Possible Biomoleular Explanation. Neurol India. 2019 Jul-Aug; 67(4):1142.